Onfasprodil (MIJ821) is a drug delivered via intravenous infusion that is designed as a fast-acting treatment for treatment-resistant depression. It works as a negative allosteric modulator of the NMDA receptor subunit 2B (NR2B). The drug is developed by Novartis.[1][2]
References
- Baltazar Gomez-Mancilla, Jeffrey A. Levy, Subramanian Ganesan, Thomas Faller, Gil Issachar, Ziv Peremen, Offir Laufer, Revital Shani-Hershkovich. MIJ821 (onfasprodil) in healthy volunteers: First-in-human, randomized, placebo-controlled study (single ascending dose and repeated intravenous dose) Clinical and Translational Science, November 2023^
- Hitoshi Osaka, Tetsufumi Kanazawa. Emerging trends in antipsychotic and antidepressant drug development: Targeting nonmonoamine receptors and innovative mechanisms Psychiatry and Clinical Neurosciences Reports, December 2023^